These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30416684)

  • 21. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.
    Singh SP; Pillai SY; de Bruijn MJW; Stadhouders R; Corneth OBJ; van den Ham HJ; Muggen A; van IJcken W; Slinger E; Kuil A; Spaargaren M; Kater AP; Langerak AW; Hendriks RW
    Oncotarget; 2017 Sep; 8(42):71981-71995. PubMed ID: 29069762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
    Shorer Arbel Y; Katz BZ; Gabizon R; Shraga A; Bronstein Y; Kamdjou T; Globerson Levin A; Perry C; Avivi I; London N; Herishanu Y
    Front Oncol; 2021; 11():646971. PubMed ID: 34055615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
    Burger JA
    Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance.
    Tissino E; Bomben R; Gattei V; Zucchetto A
    Clin Cancer Res; 2023 Sep; 29(18):3560-3562. PubMed ID: 37439706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
    Buhl AM; Cambier JC
    J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
    Haerzschel A; Catusse J; Hutterer E; Paunovic M; Zirlik K; Eibel H; Krenn PW; Hartmann TN; Burger M
    Ann Hematol; 2016 Dec; 95(12):1979-1988. PubMed ID: 27542958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
    Wiestner A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
    Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
    Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.
    Tambaro FP; De Novellis D; Wierda WG
    J Exp Pharmacol; 2021; 13():923-935. PubMed ID: 34744463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
    Alsadhan A; Chen J; Gaglione EM; Underbayev C; Tuma PL; Tian X; Freeman LA; Baskar S; Nierman P; Soto S; Itsara A; Ahn IE; Sun C; Bibikova E; Hartmann TN; Mhibik M; Wiestner A
    Clin Cancer Res; 2023 Sep; 29(18):3612-3621. PubMed ID: 37227160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
    Paillassa J; Safa F; Troussard X
    Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.
    Khan WN
    Immunol Res; 2001; 23(2-3):147-56. PubMed ID: 11444380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
    Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
    Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.